{
    "id": 32449,
    "fullName": "RET L881V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RET L881V lies within the protein kinase domain of the Ret protein (UniProt.org). L881V has been demonstrated to confer resistance to some RET inhibitors in the context of KIF5B-RET in cultured cells (PMID: 31118272), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "L881V",
    "createDate": "02/06/2020",
    "updateDate": "02/06/2020",
    "referenceTranscriptCoordinates": {
        "id": 187550,
        "transcript": "NM_020975",
        "gDna": "chr10:g.43120114C>G",
        "cDna": "c.2641C>G",
        "protein": "p.L881V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET L881V demonstrated resistance to treatment with Caprelsa (vandetinib) in culture (PMID: 31118272).",
            "molecularProfile": {
                "id": 34992,
                "profileName": "KIF5B - RET RET L881V"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20265,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) treatment inhibited the growth of cells co-expressing KIF5B-RET and RET L881V in culture (PMID: 31118272).",
            "molecularProfile": {
                "id": 34992,
                "profileName": "KIF5B - RET RET L881V"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20268,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET L881V demonstrated resistance to treatment with Lenvima (lenvatinib) in culture (PMID: 31118272).",
            "molecularProfile": {
                "id": 34992,
                "profileName": "KIF5B - RET RET L881V"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20267,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET L881V demonstrated resistance to treatment with Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31118272).",
            "molecularProfile": {
                "id": 34992,
                "profileName": "KIF5B - RET RET L881V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34991,
            "profileName": "RET L881V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34992,
            "profileName": "KIF5B - RET RET L881V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 187551,
            "transcript": "NM_020630",
            "gDna": "chr10:g.43120114C>G",
            "cDna": "c.2641C>G",
            "protein": "p.L881V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 187550,
            "transcript": "NM_020975",
            "gDna": "chr10:g.43120114C>G",
            "cDna": "c.2641C>G",
            "protein": "p.L881V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}